CP21R7
Based on 7 publication(s) in Google Scholar
CP21R7 is potent GSK-3β inhibitor, with an IC50 of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC50 of 1900 nM.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.74%
- CAS. Nr.: 125314-13-8
- Formel: C19H15N3O2
- Molecular Weight:317.34
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) CP21R7
More- Theranostics. 2026 Apr 22;16(11):6164-6183. [Abstract]
- Small. 2023 Apr;19(16):e2207194. [Abstract]
- J Mol Cell Cardiol. 2023 Mar:176:21-32. [Abstract]
- J Mol Cell Cardiol. 2022 Feb:163:81-96. [Abstract]
- Braz J Med Biol Res. 2024 Aug 19:57:e13796. [Abstract]
- STAR Protoc. 2022 Apr 13;3(2):101296. [Abstract]
- SSRN. 2025 Jan 15.
Customer Validation & Images
-
IF
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
WB
Biologische Aktivität
|
GSK-3β 1.8 nM (IC50) |
PKCα 1900 nM (IC50) |
CP21R7 (Compound 9) is a selective inhibitor of GSK-3β, with an IC50 of 1.8 nM; the IC50 of CP21R7 against PKCα is 1900 nM[1]. CP21R7 (CP21, 3 μM) potently activates canonical Wnt signaling with highest activity. CP21 significantly increases total levels of intracellular β-catenin. CP21 combined with BMP4 induces commitment of hPSCs towards mesoderm[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 125314-13-8
-
Appearance Solid
-
Molecular Weight 317.34
-
Formel C19H15N3O2
-
Color Yellow to orange
-
SMILES
O=C1C(C2=CN(C)C3=CC=CC=C23)=C(C4=CC(N)=CC=C4)C(N1)=O
-
Synonyms
CP21
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (7)
-
Journal Impact Factor
-
Most Recent
-
Theranostics
Dual ROS modulation by MnO2-integrated collagen hydrogel enhances hiPSC-derived endothelial progenitor cell therapy for critical limb ischemia. [Abstract]2026 Apr 22;16(11):6164-6183. PMID: 42094610 -
Small
2023 Apr;19(16):e2207194. PMID: 36634971 -
J Mol Cell Cardiol
VGLL4-TEAD1 promotes vascular smooth muscle cell differentiation from human pluripotent stem cells via TET2. [Abstract]2023 Mar:176:21-32. PMID: 36657637 -
J Mol Cell Cardiol
YAP inhibition promotes endothelial cell differentiation from pluripotent stem cell through EC master transcription factor FLI1. [Abstract]2022 Feb:163:81-96. PMID: 34666000 -
Braz J Med Biol Res
GSK3B inhibition reduced cervical cancer cell proliferation and migration by modulating the PI3K/Akt signaling pathway and epithelial-to-mesenchymal transition. [Abstract]2024 Aug 19:57:e13796. PMID: 39166606
CP21R7 purchased from MedChemExpress. Usage Cited in: Braz J Med Biol Res. 2024 Aug 19:57:e13796. [Abstract]
EdU assay showing the proliferation of HeLa cells with CP21R7 (0.2, 0.5 μM) treatment.
CP21R7 purchased from MedChemExpress. Usage Cited in: Braz J Med Biol Res. 2024 Aug 19:57:e13796. [Abstract]
Scratch assay showing migration in HeLa cells with CP21R7 (0.5 μM) treatment at various time points.
CP21R7 purchased from MedChemExpress. Usage Cited in: Braz J Med Biol Res. 2024 Aug 19:57:e13796. [Abstract]
Statistical analysis of CCK-8 assay of the viability of HeLa cells with CP21R7 (0.2. 0.5 μM) treatment.
CP21R7 purchased from MedChemExpress. Usage Cited in: Braz J Med Biol Res. 2024 Aug 19:57:e13796. [Abstract]
Photograph of xenograft tumors at study endpoint treated with CP21R7 (5 mg/kg, i.v.).
CP21R7 purchased from MedChemExpress. Usage Cited in: Braz J Med Biol Res. 2024 Aug 19:57:e13796. [Abstract]
WB analysis detecting the p-Akt protein levels in HeLa cells treated with CP21R7 (0.2, 0.5 μM).
-
STAR Protoc
Protocol for inducible piggyBac transposon system for efficient gene overexpression in human pluripotent stem cells. [Abstract]2022 Apr 13;3(2):101296. PMID: 35496784 -
Lösungsmittel & Löslichkeit
DMSO : ≥ 32 mg/mL (100.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.88 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Gong L, et al. Discovery of potent and bioavailable GSK-3beta inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1693-6. [Content Brief]
[2]. Patsch C, et al. Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nat Cell Biol. 2015 Aug;17(8):994-1003. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1512 mL | 15.7560 mL | 31.5119 mL | 78.7799 mL |
| 5 mM | 0.6302 mL | 3.1512 mL | 6.3024 mL | 15.7560 mL | |
| 10 mM | 0.3151 mL | 1.5756 mL | 3.1512 mL | 7.8780 mL | |
| 15 mM | 0.2101 mL | 1.0504 mL | 2.1008 mL | 5.2520 mL | |
| 20 mM | 0.1576 mL | 0.7878 mL | 1.5756 mL | 3.9390 mL | |
| 25 mM | 0.1260 mL | 0.6302 mL | 1.2605 mL | 3.1512 mL | |
| 30 mM | 0.1050 mL | 0.5252 mL | 1.0504 mL | 2.6260 mL | |
| 40 mM | 0.0788 mL | 0.3939 mL | 0.7878 mL | 1.9695 mL | |
| 50 mM | 0.0630 mL | 0.3151 mL | 0.6302 mL | 1.5756 mL | |
| 60 mM | 0.0525 mL | 0.2626 mL | 0.5252 mL | 1.3130 mL | |
| 80 mM | 0.0394 mL | 0.1969 mL | 0.3939 mL | 0.9847 mL | |
| 100 mM | 0.0315 mL | 0.1576 mL | 0.3151 mL | 0.7878 mL |
CP21R7 Related Classifications
HY-100207 Related Classifications
Powered by Bioz